<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099058</url>
  </required_header>
  <id_info>
    <org_study_id>M14-237</org_study_id>
    <secondary_id>2014-003154-14</secondary_id>
    <nct_id>NCT02099058</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and&#xD;
      preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib,&#xD;
      erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met.&#xD;
      Enrollment is closed for the monotherapy arms, Arm A, and Arm D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2014</start_date>
  <completion_date type="Anticipated">December 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>The RPTD of ABBV-399 when administered as monotherapy and in combination with osimertinib, erlotinib or nivolumab will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum observed plasma concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time to Cmax (Tmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half life</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Terminal elimination half life.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (21-day dosing cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy Telisotuzumab vedotin(28-day dosing cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Erlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telisotuzumab vedotin to be evaluated with Osimertinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>It is administered orally everyday.</description>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>It is an intravenous infusion administered every 14 days.</description>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telisotuzumab vedotin</intervention_name>
    <description>It is administered by infusion in 21-day dosing cycles.</description>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
    <arm_group_label>Monotherapy Telisotuzumab vedotin (21-day dosing cycles)</arm_group_label>
    <other_name>ABBV-399</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telisotuzumab vedotin</intervention_name>
    <description>It is administered by infusion in 28-day dosing cycles.</description>
    <arm_group_label>Arm D (Telisotuzumab vedotin plus Nivolumab)</arm_group_label>
    <arm_group_label>Arm E (Telisotuzumab vedotin plus Osimertinib)</arm_group_label>
    <arm_group_label>Monotherapy Telisotuzumab vedotin(28-day dosing cycles)</arm_group_label>
    <other_name>ABBV-399</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>It is administered orally everyday.</description>
    <arm_group_label>Arm A (Telisotuzumab vedotin plus Erlotinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have advanced Non-Small Cell Lung Cancer (NSCLC) that is not amenable&#xD;
             to surgical resection or other approved therapeutic options that have demonstrated&#xD;
             clinical benefit.&#xD;
&#xD;
          -  Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0&#xD;
             to 2.&#xD;
&#xD;
          -  Participant must have measurable disease per Response Evaluation Criteria In Solid&#xD;
             Tumors (RECIST) version 1.1.&#xD;
&#xD;
          -  Participant has archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor&#xD;
             tissue confirmed available for analyses.&#xD;
&#xD;
          -  Participant has adequate bone marrow, renal, and hepatic function.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at baseline.&#xD;
&#xD;
          -  Participants in the combination therapy arms A and D must be eligible to receive&#xD;
             erlotinib, or nivolumab per most locally approved labeling, or at the discretion of&#xD;
             the Investigator.&#xD;
&#xD;
          -  Participants in the combination therapy Arm E must satisfy following criteria.&#xD;
&#xD;
               -  Participant must have metastatic/locally advanced nonsquamous NSCLC with&#xD;
                  documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R,&#xD;
                  with or without T790M mutation, and none of the EGFR mutations known to be&#xD;
                  resistant to osimertinib.&#xD;
&#xD;
               -  Participant must have received at least 1 but no more than 2 prior regimens, one&#xD;
                  of which must have contained osimertinib. Participant must have had disease&#xD;
                  progression while on osimertinib. Only 1 prior regimen may have contained&#xD;
                  chemotherapy.&#xD;
&#xD;
               -  Participant must have available post-progression tumor tissue for central c-Met&#xD;
                  immunohistochemistry (IHC) testing.&#xD;
&#xD;
               -  Participant has adequate bone marrow function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has received anticancer therapy including chemotherapy, radiation therapy,&#xD;
             immunotherapy, biologic, or any investigational therapy within a period of 21 days or&#xD;
             herbal therapy within 7 days prior to the first dose of ABBV-399.&#xD;
&#xD;
          -  Participant has uncontrolled metastases to the central nervous system (CNS) based on&#xD;
             head CT or MRI. Participants with brain metastases may be eligible 2 weeks after&#xD;
             definitive therapy to all known sites of CNS disease provided they are asymptomatic&#xD;
             and either off or on a non-increasing dose (in last 2 weeks) of systemic steroids and&#xD;
             not on anticonvulsants for seizure activity directly related to progressive CNS&#xD;
             metastases.&#xD;
&#xD;
          -  Participant has history of interstitial lung disease (ILD) or pneumonitis that&#xD;
             required treatment with systemic steroids, or any evidence of active ILD or&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Participant has unresolved clinically significant adverse events &gt;= Grade 2 from prior&#xD;
             anticancer therapy, except for alopecia or anemia.&#xD;
&#xD;
          -  Participant has had major surgery within 21 days prior to the first dose of ABBV-399.&#xD;
&#xD;
          -  Participant has a clinically significant condition(s) described in the protocol.&#xD;
&#xD;
          -  History of major immunologic reaction to any Immunoglobulin G (IgG) containing agent.&#xD;
&#xD;
          -  Participant has any medical condition which in the opinion of the Investigator or&#xD;
             Medical Monitor places the participant at an unacceptably high risk for toxicities.&#xD;
&#xD;
          -  Participant is a lactating or pregnant female.&#xD;
&#xD;
          -  Participants with known active Coronavirus Disease - 2019 (COVID-19) infection.&#xD;
             Participant with signs/symptoms associated with COVID-19 infection or known exposure&#xD;
             to a confirmed case of COVID-19 infection during 14 days prior to Screening:&#xD;
&#xD;
          -  Participants enrolled on the combination therapy phase must satisfy the above&#xD;
             exclusion criteria and also the following:&#xD;
&#xD;
               -  Participants may not receive ABBV-399 in combination with osimertinib, erlotinib&#xD;
                  or nivolumab if they have any medical condition which in the opinion of the&#xD;
                  Investigator places the participant at an unacceptably high risk for toxicities&#xD;
                  from the combination.&#xD;
&#xD;
               -  Participants may not receive nivolumab if they have:&#xD;
&#xD;
                    -  Active autoimmune disease with exceptions of vitiligo, type I diabetes&#xD;
                       mellitus, hypothyroidism and psoriasis.&#xD;
&#xD;
                    -  Used systemic corticosteroids (&gt; 10 mg daily prednisone or equivalent) or&#xD;
                       other immunosuppressive medications within 14 days of study drug&#xD;
                       administration, with exception of inhaled, locally injected or topical&#xD;
                       steroids.&#xD;
&#xD;
                    -  Known immunosuppressive disease, for example human immunodeficiency virus&#xD;
                       infection or history of bone marrow transplant or chronic lymphocytic&#xD;
                       leukemia.&#xD;
&#xD;
               -  Participants may not be enrolled into the osimertinib Combination Therapy Arm E&#xD;
                  if they have the following:&#xD;
&#xD;
                    -  History of hypersensitivity to active or inactive excipients of osimertinib.&#xD;
&#xD;
                    -  History of osimertinib dose reduction to below 80 mg once a day (QD).&#xD;
&#xD;
                    -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability&#xD;
                       to swallow the formulated product, or previous significant bowel resection&#xD;
                       that would preclude adequate absorption of osimertinib.&#xD;
&#xD;
                    -  Any of the following cardiac criteria: a) Mean resting corrected QT interval&#xD;
                       (QTc) &gt; 470 ms; b) Any clinically important abnormalities in rhythm,&#xD;
                       conduction, or morphology of resting ECG, e.g., complete left bundle branch&#xD;
                       block, second- or third-degree heart block, PR interval &gt; 250 ms; c) Any&#xD;
                       factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                       events such as heart failure, hypokalemia, congenital long QT syndrome, or&#xD;
                       any concomitant medication known to prolong the QT interval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare /ID# 123761</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>City of Hope /ID# 153759</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 148295</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine /ID# 165107</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Comprehensive Cancer Center /ID# 129805</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 123759</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center /ID# 136995</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 165876</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 129804</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 168782</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 149857</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herbert Herman Cancer Center /ID# 149858</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 143798</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group-Florham Park /ID# 217651</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932-1049</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Monter Cancer Center /ID# 218170</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Weill Cornell Medical Center /ID# 218445</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center /ID# 123763</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC /ID# 129802</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 123760</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 154648</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Fairfax /ID# 165708</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen /ID# 170118</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital /ID# 165065</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hopital de la Timone /ID# 151570</name>
      <address>
        <city>Marseille CEDEX 05</city>
        <state>Bouches-du-Rhone</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy /ID# 132747</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duplicate_Istituto Romagnolo per lo Studio dei Tumori &quot;Dino Amadori&quot; - IRCCS /ID# 164077</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 217570</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 217571</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital /ID# 217333</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 217334</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital /ID# 217494</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 167175</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 167173</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hosp /ID# 217392</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

